The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Both compounds can be distinguished from typical D 2 agonists, however, because they do not cause behavioral signs associated with activation of either normosensitive or supersensitive ...

Resistance to dopamine agonists occurs in a subset of patients with prolactin-secreting pituitary tumors. The resistance is mediated by loss of pituitary D 2 receptors and occurs in both ...

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h ...